These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30076000)

  • 41. Secondary metabolites from Isodon ternifolius (D. Don) Kudo and their anticancer activity as DNA topoisomerase IB and Tyrosyl-DNA phosphodiesterase 1 inhibitors.
    Zhang HL; Zhang Y; Yan XL; Xiao LG; Hu DX; Yu Q; An LK
    Bioorg Med Chem; 2020 Jun; 28(11):115527. PubMed ID: 32345458
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New Dual Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 and 2 Based on Deoxycholic Acid: Design, Synthesis, Cytotoxicity, and Molecular Modeling.
    Salomatina OV; Kornienko TE; Zakharenko AL; Komarova NI; Achara C; Reynisson J; Salakhutdinov NF; Lavrik OI; Volcho KP
    Molecules; 2024 Jan; 29(3):. PubMed ID: 38338326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tyrosyl-DNA phosphodiesterase 1 targeting for modulation of camptothecin-based treatment.
    Beretta GL; Cossa G; Gatti L; Zunino F; Perego P
    Curr Med Chem; 2010; 17(15):1500-8. PubMed ID: 20166932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tyrosyl-DNA phosphodiesterase 2 (TDP2) repairs topoisomerase 1 DNA-protein crosslinks and 3'-blocking lesions in the absence of tyrosyl-DNA phosphodiesterase 1 (TDP1).
    Tsuda M; Kitamasu K; Kumagai C; Sugiyama K; Nakano T; Ide H
    DNA Repair (Amst); 2020; 91-92():102849. PubMed ID: 32460231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Lipophilic Purine Nucleoside-Tdp1 Inhibitor-Enhances DNA Damage Induced by Topotecan In Vitro and Potentiates the Antitumor Effect of Topotecan In Vivo.
    Chernyshova IA; Zakharenko AL; Kurochkin NN; Dyrkheeva NS; Kornienko TE; Popova NA; Nikolin VP; Ilina ES; Zharkov TD; Kupryushkin MS; Oslovsky VE; Drenichev MS; Lavrik OI
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615517
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adamantane-Monoterpenoid Conjugates Linked via Heterocyclic Linkers Enhance the Cytotoxic Effect of Topotecan.
    Munkuev AA; Dyrkheeva NS; Kornienko TE; Ilina ES; Ivankin DI; Suslov EV; Korchagina DV; Gatilov YV; Zakharenko AL; Malakhova AA; Reynisson J; Volcho KP; Salakhutdinov NF; Lavrik OI
    Molecules; 2022 May; 27(11):. PubMed ID: 35684313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Dual-Sensor-Based Screening System for In Vitro Selection of TDP1 Inhibitors.
    Jakobsen AK; Keller JG; Gonzalez M; Martin-Encinas E; Palacios F; Alonso C; Knudsen BR; Stougaard M
    Sensors (Basel); 2021 Jul; 21(14):. PubMed ID: 34300575
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures.
    Davies DR; Interthal H; Champoux JJ; Hol WG
    J Mol Biol; 2002 Dec; 324(5):917-32. PubMed ID: 12470949
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual DNA topoisomerase 1 and tyrosyl-DNA phosphodiesterase 1 inhibition for improved anticancer activity.
    Zakharenko A; Dyrkheeva N; Lavrik O
    Med Res Rev; 2019 Jul; 39(4):1427-1441. PubMed ID: 31004352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of human tyrosyl-DNA phosphodiesterase by aminoglycoside antibiotics and ribosome inhibitors.
    Liao Z; Thibaut L; Jobson A; Pommier Y
    Mol Pharmacol; 2006 Jul; 70(1):366-72. PubMed ID: 16618796
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2).
    Wang P; Elsayed MSA; Plescia CB; Ravji A; Redon CE; Kiselev E; Marchand C; Zeleznik O; Agama K; Pommier Y; Cushman M
    J Med Chem; 2017 Apr; 60(8):3275-3288. PubMed ID: 28418653
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topoteсan on in vivo tumor models.
    Zakharenko AL; Luzina OA; Sokolov DN; Kaledin VI; Nikolin VP; Popova NA; Patel J; Zakharova OD; Chepanova AA; Zafar A; Reynisson J; Leung E; Leung IKH; Volcho KP; Salakhutdinov NF; Lavrik OI
    Eur J Med Chem; 2019 Jan; 161():581-593. PubMed ID: 30396105
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison.
    He X; van Waardenburg RCAM; Babaoglu K; Price AC; Nitiss KC; Nitiss JL; Bjornsti MA; White SW
    J Mol Biol; 2007 Sep; 372(4):1070-1081. PubMed ID: 17707402
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening.
    Lountos GT; Zhao XZ; Kiselev E; Tropea JE; Needle D; Pommier Y; Burke TR; Waugh DS
    Nucleic Acids Res; 2019 Nov; 47(19):10134-10150. PubMed ID: 31199869
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dehydroabietylamine-based thiazolidin-4-ones and 2-thioxoimidazolidin-4-ones as novel tyrosyl-DNA phosphodiesterase 1 inhibitors.
    Kovaleva K; Mamontova E; Yarovaya O; Zakharova O; Zakharenko A; Lavrik O; Salakhutdinov N
    Mol Divers; 2021 Nov; 25(4):2389-2397. PubMed ID: 32833106
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New inhibitors of tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 7-hydroxycoumarin and monoterpenoid moieties.
    Khomenko T; Zakharenko A; Odarchenko T; Arabshahi HJ; Sannikova V; Zakharova O; Korchagina D; Reynisson J; Volcho K; Salakhutdinov N; Lavrik O
    Bioorg Med Chem; 2016 Nov; 24(21):5573-5581. PubMed ID: 27658793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform.
    Murai J; Marchand C; Shahane SA; Sun H; Huang R; Zhang Y; Chergui A; Ji J; Doroshow JH; Jadhav A; Takeda S; Xia M; Pommier Y
    DNA Repair (Amst); 2014 Sep; 21():177-82. PubMed ID: 24794403
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Tyrosyl-DNA Phosphodiesterase 1 Is a New Player in Repair of Apurinic/Apyrimidinic Sites].
    Rechkunova NI; Lebedeva NA; Lavrik OI
    Bioorg Khim; 2015; 41(5):531-8. PubMed ID: 26762090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel TDP1 Inhibitors: Disubstituted Thiazolidine-2,4-Diones Containing Monoterpene Moieties.
    Ivankin DI; Kornienko TE; Mikhailova MA; Dyrkheeva NS; Zakharenko AL; Achara C; Reynisson J; Golyshev VM; Luzina OA; Volcho KP; Salakhutdinov NF; Lavrik OI
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay.
    Marchand C; Lea WA; Jadhav A; Dexheimer TS; Austin CP; Inglese J; Pommier Y; Simeonov A
    Mol Cancer Ther; 2009 Jan; 8(1):240-8. PubMed ID: 19139134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.